NHSE and NHSI are currently focused on communicating proactively about the launch of biosimilars for Adalimumab which will be introduced into the NHS from October 2018 onwards and which may affect up to 46,000 patients in England.

NHS England will be publishing an update for the NHS every month which will be published on the Specialist Pharmacy Service's RMOC pages:

The second briefing is here:

The first briefing is here: